DAWN Day One Biopharmaceuticals, Inc.
FY2025 10-K
Day One Biopharmaceuticals, Inc. (DAWN) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Development and commercialization of targeted oncologic therapies for pediatric and adult patients with life-threatening diseases, focusing on breakthrough medicines
- • New emphasis: Commercial launch of FDA-approved OJEMDA (tovorafenib) for relapsed/refractory pediatric low-grade glioma, only once-weekly systemic pLGG therapy
Risk Factors
- • Regulatory risk: Dependency on FDA approval and exclusivity for OJEMDA, with increased product revenue $155.4M driven by U.S. sales
- • Macroeconomic risk: Potential impact from global economic volatility, inflation, trade barriers, and geopolitical conflicts affecting capital raising efforts
Financial SummaryXBRL
Revenue
$158M
Net Income
-$107M
Operating Margin
-80.8%
Net Margin
-67.8%
ROE
-24.3%
Total Assets
$508M
EPS (Diluted)
$-1.04
Operating Cash Flow
-$104M
Source: XBRL data from Day One Biopharmaceuticals, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Day One Biopharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.